ClinicalTrials.gg
Active, not recruitingNCT04780217Updated Mar 4, 2024

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

A Phase 1/2 interventional study of T3011 in Solid Tumor, Hepatocellular Carcinoma and Colorectal Cancer, sponsored by ImmVira Pharma Co. Ltd. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.

Primary conditionnone(registry's first term: Carcinoma, Hepatocellular)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Carcinoma, Hepatocellular, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by ImmVira Pharma Co. Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors

Read the detailed description

This is a multicenter, open-label study conducted in two phases (as outlined in the subsections below):

Phase 1: T3011 administered intravenously as a single agent in subjects with pathologically confirmed locally recurrent or metastatic solid tumors, who have failed or declined SOC treatment. Phase 1 will use a 3+3 design to evaluate escalating doses of single agent T3011. Cohorts of three subjects will be enrolled at each T3011 dose level with expansion to six subjects, if necessary, to assess toxicity. Total enrollment will depend on the toxicities observed, with approximately 36-42 evaluable subjects enrolled in phase 1.

Phase 2a: An expansion study will be conducted based on phase 1 results.

02

Conditions studied

  • Solid Tumor
  • Hepatocellular Carcinoma
  • Colorectal Cancer
  • NSCLC
  • Ovarian Cancer
  • Endometrial Cancer

Keywords

  • solid tumor
03

In context

Lead sponsor

ImmVira Pharma Co. Ltd is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must meet the following criteria for inclusion:

  1. Subjects with one of the following cancers:

    • confirmed, locally recurrent or solid tumors, including, but not limited to NSCLC, hepatocellular carcinoma, colorectal cancer, ovarian cancer and endometrial cancer (Phase 1).
  2. Disease progression on or unlikely to respond to SOC therapy at the discretion of the Investigator. SOC may include, but is not limited to, chemotherapy, targeted therapy or immunotherapy.
  3. Age 18 years or older.
  4. At least one target lesion per version 1.1.

    • A previously irradiated lesions can be considered as target lesion only if PD has been unequivocally documented at that site since radiation.
  5. (ECOG) performance status 0 - 1.
  6. ≥ 12 weeks.
  7. Adequate bone marrow function defined by (ANC) of ≥ 1.5 × 109/L, count of ≥ 100 × 109/L, and (Hb) of ≥ 8.5 g/dL.
  8. Adequate hepatic function defined as (AST)/alanine aminotransferase (ALT) ≤ 3 × (ULN) and total ≤ 1.5 × ULN (except subjects with Gilbert's Syndrome, wherein total bilirubin \< 3.0 mg/dL is acceptable).
  9. Adequate renal function defined as > 50 mL/min as determined by the Cockcroft-Gault equation.
  10. Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile), or be at least 2 years , or commit to using 2 acceptable forms of (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 6 months following the last dose of study treatment. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment.
  11. Women of (WCBP) must have a negative serum pregnancy test at Screening within 14 days of dosing with T3011 and a negative urine pregnancy test pre-dose on C1D1 (assessment not required at C1D1 if completed within the previous 7 days of C1D1).

    Note: A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).

  12. Last dose of previous anticancer therapy ≥ 21 days; radiotherapy > 14 days (except prior focal palliative radiotherapy must have been completed at least 1 week prior to the first dose of study treatment); major surgery > 21 days; or last dose of therapy with tyrosine kinase inhibitors within 5 times the half-life of the inhibitor prior to first dose of study treatment. Last dose of ≥ 14 days, as long as treatment related toxicities resolve to ≤ Grade 1.
  13. Resolution of all prior anticancer therapy toxicities (except for alopecia) to ≤ version 5.0 Grade 1.

    Note: subjects with immune-mediated endocrinopathies on replacement therapy are eligible. Subjects with toxicities attributed to the prior anticancer therapy and not expected to resolve, such as neuropathy or ototoxicity after platinum-based therapy, are permitted to enroll. Subjects with other toxicities > CTCAE version 5.0 Grade 1 may be enrolled with approval from the sponsor.

  14. Willingness to provide pre- and post-treatment fresh tumor specimens, if tumor is easily accessible, as specified in the Schedule of Assessments. Subject is eligible to participate without providing fresh tumor biopsy specimens, with approval from the Medical Monitor.
  15. Capable of understanding and complying with protocol requirements.
  16. Signed and dated institutional review board/independent ethics committee (IRB/IEC) approved form (ICF) before any protocol-directed screening procedures are performed.

Exclusion criteria

Exclusion Criteria:

Subjects are to be excluded from the study if they meet any of the following criteria:

  1. Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or gene therapy.
  2. Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.
  3. Subjects with rapidly disease progression, defined as subjects who cannot tolerate interruption of systemic antitumor therapy for at least 8 weeks, according to the investigator's judgment.
  4. Previous intolerance to anti-PD-(L)1 monoclonal antibody or previous history of immunotherapy induced non-infectious pneumonitis/interstitial lung disease.
  5. Requires continued concurrent systemic therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Topical use of drugs against HSV are allowed.
  6. Live, attenuated vaccines within 4 weeks prior to initiation of study treatment (subjects vaccinated with inactivated vaccines can be enrolled).
  7. Primary or acquired immunodeficient states (leukemia, lymphoma, [HIV]/acquired immunodeficiency syndrome [AIDS]).
  8. Active infection requiring systemic treatment.
  9. Pregnant or lactating.
  10. Splenectomy, previous allogenic tissue/solid organ transplant.
  11. Positive serological test of virus (HBV) or virus at Screening.

    • Subjects who test positive for anti-hepatitis C antibody (anti-HCV) but negative for HCV ribonucleic acid (RNA) are considered eligible to participate in the study.
    • Subjects with infection of hepatitis B (positive hepatitis B surface antigen [HBsAg] result) will be excluded. Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible.
  12. Active disease or other medical conditions (e.g., active interstitial lung disease/pneumonitis or eczema, psoriasis, or other dermatologic disorders) requiring chronic systemic (> 10 mg/day prednisone or equivalent) or therapy within 4 weeks prior to first administration of study treatment (unless agreed otherwise between the Medical Monitor and the Investigator on a case-by-case basis). Non-systemic corticosteroids (eg, topical, inhaled) are allowed.
  13. Subjects with untreated and/or symptomatic central nervous system (CNS) disease, primary CNS tumors, or spinal cord compression. However, subjects with brain/ who have undergone surgery or radiotherapy, whose disease is stable and who have been on a stable dose of corticosteroids (≤ 10 mg prednisone or equivalent) for at least 4 weeks prior to the first administration of study treatment will be eligible.
  14. History of another primary malignant tumor, except the following: 1) the patient has undergone potentially curative therapy with no evidence of that disease and recurrence for 3 years prior to the first dose of study treatment; 2) Adequately treated non-melanoma skin cancer or lentigo with no evidence of ; 3) Adequately treated carcinoma in situ without evidence of disease.
  15. Subjects with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention. Subject may be eligible to participate following discussion with investigator and approval from the sponsor.
  16. Unexplained >38.5℃ fever (If the fever is caused by the tumor according to the investigator's judgment, the patient can be enrolled) occurs during the screening period or on the day of administration, which in the judgment of investigator, would interfere with patient participation in the study or evaluation of patient's efficacy.
  17. History of seizure disorders within 6 months prior to Screening.
  18. Active oral or skin herpes lesion at Screening.
  19. Plan to receive any other anti-tumor therapy (including herbal therapy that has anti-tumor effects) during treatment with study drug.
  20. History of congestive heart failure (> Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias.
  21. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or monoclonal antibody or their .
  22. History of psychiatric disorders that would interfere with cooperation with the requirements of the trial or is still requiring for medication control.
  23. History of substance abuse (including alcohol) within 6 months prior to signing .
  24. Other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Phase 1

    T3011 Single Agent Dose Escalation in participants with solid tumors

    Biological: T3011

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of escalating doses of single agent IV T3011 Characterize DLTs and identify the MTD and/or the RP2D of single agent IV T3011

    Number of participants with Adverse Events (TEAEs, SAEs, AESIs), with abnormal clinically significant vital signs, with abnormal physical examination findings and abnormal laboratory tests results

    Time frame: Up to 2 years from first dose of T3011

Secondary outcomes

  1. Evaluate the immunogenicity of single agent IV T3011.

    Measurement of ADAs and Nabs of IL-12, anti-PD-1 antibody and HSV-1 (test Nabs when ADAs are positive).

    Time frame: Up to 2 years from first dose of T3011

  2. Overall response rate (ORR)

    Defined as the percentage of subjects who have best overall response (BOR) as CR or partial response (PR), as determined according to RECIST v1.1. CR or PR will be claimed only if the criteria for each are met at a subsequent time point at 4-8 weeks later.

    Time frame: Up to 2 years from first dose of T3011

  3. Disease control rate (DCR)

    Defined as the percentage of subjects who have BOR as CR or PR or stable disease (SD) (if a subject develops SD, it needs to be confirmed at least 6 weeks later, that is, SD lasts at least 6 weeks), as determined according to RECIST v1.1.

    Time frame: Up to 2 years from first dose of T3011

  4. Duration of response (DOR)

    Defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever comes first), as determined according to RECIST v1.1

    Time frame: Up to 2 years from first dose of T3011

  5. Progression-free survival (PFS)

    Defined as the time from the date of first treatment to the first occurrence of disease progression or death from any cause (whichever comes first), as determined according to RECIST v1.1.

    Time frame: Up to 2 years from first dose of T3011

  6. Overall Survival (OS)

    OS is defined as the time from enrollment to death from any cause.

    Time frame: Up to 2 years from first dose of T3011

  7. time to treatment failure(TTF)

    Defined as a composite endpoint measuring time from the date of first treatment to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death.

    Time frame: Up to 2 years from first dose of T3011

  8. PFS2

    Defined as the time from the date of initiation of new antitumor therapy to the first occurrence of disease progression after new antitumor therapy or death from any cause (whichever comes first)

    Time frame: Up to 2 years from first dose of T3011

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Mar 2025, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2021
First posted
Mar 3, 2021
StartActual
Aug 10, 2021
Primary completionEst.
Mar 2025
CompletionEst.
Aug 2025
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04780217
Lead sponsor
ImmVira Pharma Co. Ltd
Responsible party
Sponsor
First posted
Mar 3, 2021
Start date
Aug 10, 2021
Primary completion
Mar 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Mar 4, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011

Start the discussion